SVB Leerink analyst Ami Fadia downgraded Endo to Market Perform from Outperform due to a further step-down in the generics business in 2019, and the potential overhang from the opioid litigation. The analyst also lowered her price target on the shares to $10 from $13.
https://thefly.com/landingPageNews.php?id=2874305
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.